This randomized, single-blinded study compared the impact of different ablation strategies on the long-term procedure outcomes such as arrhythmia recurrence and change in quality of life in patients with coexistent atrial fibrillation and atrial flutter (AFL). In the presence of concurrent atrial fibrillation and AFL, although the literature is limited, the reported results support a variety of procedural approaches. They include either pulmonary vein antrum isolation for atrial fibrillation or cavotricuspid isthmus ablation for AFL or a combined approach of pulmonary vein antrum isolation plus cavotricuspid isthmus ablation. The optimal strategy remains unclear, prompting the present study. Our findings clearly suggested that atrial fibrillation ablation with or without AFL ablation is more effective than AFL ablation alone in achieving recurrence-free survival and improving quality of life. Furthermore, our results indicated that pulmonary vein antrum isolation alone may have an efficacy comparable to that pulmonary vein antrum isolation plus AFL ablation in controlling both arrhythmias and improving quality of life. Also worth mentioning is the fact that this was the first study with patients blinded to the procedure type to show that improvement in quality of life correlated with clinical freedom from arrhythmia recurrence. Although this study had certain limitations, it was an attempt to explore the best ablation option for the elimination of arrhythmias in patients with coexistent atrial fibrillation and AFL. There is a pressing need for optimization of a safe and effective ablation approach that would successfully cure both arrhythmias and save the patients from the cost and the stress of recurrences and repeat ablations. Our study is a step forward in that direction. See p 1853.
Long-Term Survival and Repeat Coronary Revascularization in Dialysis Patients After Surgical and Percutaneous Coronary Revascularization With DrugEluting and Bare Metal Stents in the United States
Dialysis patients are at high risk for cardiovascular morbidity and mortality. Although coronary artery revascularization procedures are frequently performed in this high-risk population, clinical trials comparing the outcomes of coronary artery bypass graft surgery or percutaneous coronary intervention have never been performed in dialysis patients. In this study, observational data from the United States Renal Data System are presented on survival after surgical and percutaneous coronary revascularization. Among dialysis patients undergoing coronary revascularization, in-hospital mortality was higher for coronary artery bypass graft patients, but long-term survival was superior with internal mammary grafts. In-hospital mortality was lower for patients who received drug-eluting stents, but the probability of repeat revascularization was higher. Clinical decisions on coronary revascularization in dialysis patients should be individualized. See p 1861.
Long-Term Survival of Patients Undergoing Mitral Valve Repair and Replacement: A Longitudinal Analysis of Medicare Fee-for-Service Beneficiaries
Despite the established superiority of mitral repair over replacement, its adoption in the treatment of elderly patients has not been uniform. Whereas American College of Cardiology/ American Heart Association (ACC/AHA) guidelines recommend early surgery for mitral regurgitation in the "nonelderly," special consideration is urged for the "elderly," that they be treated medically unless severely symptomatic. These guideline recommendations stem from older studies citing operative mortality rates of 14% to 20%. Our article provides a timely update on the outcomes of 47 279 elderly patients (median age, 75 years) undergoing mitral valve surgery. Operative mortality was 7.1%, which is substantially lower than that reported in the ACC/AHA guidelines for the elderly. Furthermore, operative mortality for patients who underwent repair was 3.9% compared with 8.9% for replacement. Patients who underwent repair appear to have a life expectancy similar to that of the age-and sex-matched US population, even in the cohort ≥75 years of age. Current guidelines strongly recommend referral to mitral valve surgery in symptomatic patients, preferably before the onset of left ventricular dysfunction and congestive heart failure. It appears that deviations often occur in the evaluation and treatment of mitral regurgitation in the elderly. In this cohort, 60% of patients had a prior diagnosis of heart failure, an evident delay in referral to intervention. Given the favorable outcomes of elderly patients undergoing mitral valve surgery, especially mitral valve repair, an approach of earlier identification and surgical referral appears justified regardless of age. These findings have relevance both to cardiologists treating mitral valve disease and potentially to the generation of new guideline recommendations. See p 1870.
Reestablishment of the Endothelial Lining by Endothelial Cell Therapy Stabilizes Experimental Abdominal Aortic Aneurysms
Abdominal aortic aneurysms (AAAs) are characterized by a thinning of the aortic media with rarefaction of vascular smooth muscle cells and extracellular matrix destruction triggered by inflammation, oxidative stress, and proteolysis. Another structural feature of AAAs is the presence of a thick intraluminal thrombus with loss of the endothelial monolayer in the lumen. Although the association of luminal thrombus and AAA progression and rupture has been recognized, the contribution of endothelial loss has received little attention. Here, we show that endovascular delivery of mature aortic endothelial cells or peripheral blood-derived endothelial progenitor cells reduces the expansion of experimental AAAs while reestablishing the integrity of the endothelial monolayer. In our study, the recovery of the luminal endothelium is associated with the reconstitution of new arterial wall replacing the thrombus. The protective effects of endothelial cell therapy rely on the release of stabilizing factors secreted by Volume 127 ◼ Number 18 ◼ May 7, 2013 Importantly, from a clinical translational point of view, these results were replicated using a pharmacological Nox inhibitor, GKT137381, which is already in clinical development. Furthermore, the in vivo data were complemented by in vitro studies using siRNA silencing to knockdown selectively Nox1 or Nox 4, and we were able to replicate the effects on reactive oxygen species formation, inflammation, and fibrosis as observed in vivo. These studies provide the first definitive evidence that Nox1 is a critical target for advanced atherosclerosis, particularly in the diabetic context, and that this isoform is pharmacologically targetable, thereby increasing the clinical translational potential of these findings. See p 1888.
